MedTrace Logo

Loncastuximab Tesirine in WM

NCT05190705 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-05-20

No results posted yet for this study

Summary

This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM).

The name of the study drug involved in this study is:

* Loncastuximab tesirine

Conditions

Interventions

DRUG

Loncastuximab Tesirine

Administered by intravenous infusion

DRUG

Dexamethasone

Taken orally or administered by intravenous infusion

Sponsors & Collaborators

  • ADC Therapeutics S.A.

    collaborator INDUSTRY

  • Shayna Sarosiek, MD

    lead OTHER

Principal Investigators

  • Shayna Sarosiek, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-17
Primary Completion
2026-05-01
Completion
2028-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05190705 on ClinicalTrials.gov